

**In the Claims**

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by double bracketing. This listing of claims will replace all prior versions and listings of claims in the application.

1 - 17. (Canceled)

18. (Currently amended) A pharmaceutical preparation comprising:  
a covalent conjugate of *cis*-docosahexaenoic acid and [[a noncentral nervous system active]] an agent, and  
a pharmaceutically acceptable carrier, wherein the [[noncentral nervous system active]] agent is calcitriol, 22-oxacalcitriol, fluocalcitriol, calcipotriol, calcipotriene, calcifediol, secalciferol, dihydrotachysterol, 20-epi-1,25 dihydroxyvitamin D3, 1 alpha-hydroxyvitamin D2, or alfacalcidol.

19 - 30. (Canceled)

31. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is calcitriol.

32. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is 22-oxacalcitriol.

33. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is fluocalcitriol.

34. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is calcipotriol.

35. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is calcipotriene.
36. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is calcifediol.
37. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is secalciferol.
38. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is dihydrotachysterol.
39. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is 20-epi-1,25 dihydroxyvitamin D3.
40. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is 1 alpha-hydroxyvitamin D2.
41. (Currently amended) The pharmaceutical preparation of claim 18, wherein the [[noncentral nervous system active]] agent is alfacalcidol.